Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,510
Stocks News & Analysis
stocks
2 undervalued ASX shares report
stocks
Turmoil at WiseTech
video
What does the RBA rate cut mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,494.50 | 65.60 | -0.77% |
CAC 40 | 8,090.99 | 63.52 | -0.78% |
DAX 40 | 22,425.93 | 138.37 | 0.62% |
Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
FTSE 100 | 8,658.98 | 0.39 | -0.00% |
HKSE | 22,998.69 | 342.92 | -1.47% |
NASDAQ | 19,286.93 | 237.08 | -1.21% |
Nikkei 225 | 38,345.99 | 430.95 | -1.11% |
NZX 50 Index | 12,355.74 | 175.98 | -1.40% |
S&P 500 | 5,983.25 | 29.88 | -0.50% |
S&P/ASX 200 | 8,247.00 | 61.20 | -0.74% |
SSE Composite Index | 3,359.27 | 13.76 | -0.41% |